CEO & Chairman (born 1965). CEO since 2025, Chairman since 2019. MD, PhD, Associate Professor (Karolinska Institutet). Circa 20 years of experience in venture capital focused on life science. Former Head of Life Science at SEB Venture Capital. Prior clinical and academic experience. Current assignments include CEO and board roles at Karolinska Development and Modus Therapeutics.
Non‑executive Director (born 1958). Board member since 2024. BSc Business Administration & Economics. Former CEO & founder of Intervalor; extensive financial‑sector experience
Founder & Non‑executive Director (born 1948). Board member since 2006. MD, PhD, Professor at Umeå University; >400 publications on neurosteroids.
Non‑executive Director (born 1946). Board member since 2016. Former senior roles at Chiron, Novartis, Hyperion Therapeutics; former UCSF Professor & Chief of Gastroenterology; >200 publications.
Non‑executive Director (born 1949). Board member since 2017. MPhil, PhD, DSc. >40 years in pharma & biotech; former senior roles at ICI, SmithKline Beecham; President Emeritus, British Pharmacological Society.
Non‑executive Director (born 1971). Board member since 2020. MD, PhD. Broad drug‑development experience (AstraZeneca, Shire, Medivir); current CEO of Modus Therapeutics; CSO at Karolinska Development.